Boldt J, Salomon F, Krumholz W, Hempelmann G
Abteilung Anaesthesiologie und operative Intensivmedizin, Klinikum der Justus-Liebig-Universität Giessen.
Anasth Intensivther Notfallmed. 1988 Apr;23(2):91-4.
Pharmacokinetics of mezlocillin (70 mg/kg as an infusion) were investigated in 8 patients with multiorgan failure undergoing continuous veno-venous haemofiltration (CVVH) due to acute renal failure (HF-group) in comparison to 8 intensive care patients with an uneffected renal system (control group). Mezlocillin concentration were studied in blood, ultrafiltrate and urine (control group). Elimination of mezlocillin was prolonged in the HF-group with a t1/2 of 170 min in comparison to 109 min in the control patients. No relevant absorption at the haemofilter membrane could be observed. With regard to our results a dose reduction and intermittend application of mezlocillin is suggested; in addition, monitoring of drug levels in critically ill patients becomes of increasing interest, especially during haemofiltration.
对8例因急性肾衰竭接受持续静脉-静脉血液滤过（CVVH）的多器官功能衰竭患者（HF组）和8例肾功能正常的重症监护患者（对照组）进行了美洛西林（70mg/kg静脉输注）的药代动力学研究。在对照组中，对血液、超滤液和尿液中的美洛西林浓度进行了研究。HF组美洛西林的消除时间延长，t1/2为170分钟，而对照组患者为109分钟。未观察到血液滤过膜有相关吸收。根据我们的研究结果，建议减少美洛西林剂量并间歇给药；此外，监测重症患者的药物水平变得越来越重要，尤其是在血液滤过期间。
